With a new FDA approval under its belt, United Therapeutics could have a blockbuster on its hands with the inhaled version of hypertension drug Tyvaso. The drug was approved last week for the treatment of pulmonary hypertension associated with interstitial lung disease. The original version of Tyvaso was approved to treat pulmonary arterial hypertension (PAH) in 2009. For the treatment of PAH, Tyvaso holds covered or better status for 84% of all insured lives under the pharmacy benefit. 5.7% of covered lives have preferred access to Tyvaso without utilization management restrictions.
SOURCE: MMIT Analytics, as of 5/25/22